(Q54153850)

25 May 2018

title

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. (English)

1 reference

25 May 2018

1 reference

2

1 reference

25 May 2018

Bo Ahrén

series ordinal

1

object named as

Ahrén B

1 reference

25 May 2018

author name string

Mårtensson H

series ordinal

3

1 reference

25 May 2018

Balkan B

series ordinal

4

1 reference

25 May 2018

language of work or name

English

0 references

publication date

1 September 2000

1 reference

25 May 2018

European Journal of Pharmacology

published in

1 reference

25 May 2018

volume

404

1 reference

25 May 2018

issue

1-2

1 reference

25 May 2018

page(s)

239-245

1 reference

25 May 2018

Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Effects of peptide HI on basal and stimulated insulin and glucagon secretion in the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Glucagon-like peptide-1 7-36: a physiological incretin in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Is glucagon-like peptide 1 an incretin hormone?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

10.1016/S0014-2999(00)00600-2

7 January 2021

Identifiers

DOI

1 reference

25 May 2018

PubMed ID

10980284

1 reference

25 May 2018